Build on Well-Established Antibody Discoveries
Build on Well-Established Antibody Discoveries
Build on Well-Established Antibody Discoveries
OVERVIEW SPECIFICATIONS THE PROCESS PROOF OF CONCEPT RESOURCES
Overview

Capitalize on Proven Binding Motifs

The Twist Ancestral scFv Library is a new synthetic antibody library developed using trends observed in a curated, yet broad, set of therapeutic and diagnostic antibodies. By capturing the diversity observed in examined antibody sequences and mimicking the human antibody repertoire, this library offers higher quality sequences than naïve libraries to help you identify better hits against any target.

This unique library can empower your therapeutic antibody discovery and development for any indication.

Produce robust scFv antibodies against any target
Produce robust scFv antibodies against any target
Proven, highly manufacturable framework with development liabilities removed
Fully human antibody sequences
1 x 10^9 diversity
Capitalize on binding motifs from examined antibodies
Capitalize on binding motifs from examined antibodies
Binding sites informed by 22,426 existing antibodies
Superior binding affinity and specificity
Synthetic library advantage
Synthetic library advantage
Panning to functional assays in 10-12 weeks without immunization
Focus on effective sequence space
Screen multiple targets simultaneously

Capitalize on Proven Binding Motifs

The Twist Ancestral scFv Library is a new synthetic antibody library developed using trends observed in a curated, yet broad, set of therapeutic and diagnostic antibodies. By capturing the diversity observed in examined antibody sequences and mimicking the human antibody repertoire, this library offers higher quality sequences than naïve libraries to help you identify better hits against any target.

This unique library can empower your therapeutic antibody discovery and development for any indication.

Produce robust scFv antibodies against any target
Produce robust scFv antibodies against any target
Proven, highly manufacturable framework with development liabilities removed
Fully human antibody sequences
1 x 10^9 diversity
Capitalize on binding motifs from examined antibodies
Capitalize on binding motifs from examined antibodies
Binding sites informed by 22,426 existing antibodies
Superior binding affinity and specificity
Synthetic library advantage
Synthetic library advantage
Panning to functional assays in 10-12 weeks without immunization
Focus on effective sequence space
Screen multiple targets simultaneously
Specifications
Library Specifications

The Twist Ancestral scFv Library leverages information from 22,426 existing human, monkey, and alpaca antibodies. The library excludes potential development liability motifs while selecting for optimal complementarity determining region (CDR) sequences and lengths that generate the diversity of this antibody set. The heavy chain library permutates CDR sequences from 100 unique CDR1s, 100 unique CDR2s, and 845 unique CDR3s within the human IGHV3-23 framework. The light chain library assembles diverse combinations of CDRs from 80 unique CDR1s, 80 unique CDR2s, and 400 unique CDR3s within the human IGKVK1-39 framework. When combined, the assembled heavy and light chain libraries yield a fully human scFv library with a diversity of 1 x 109.

heavy chain & light chain image
Library Specifications

The Twist Ancestral scFv Library leverages information from 22,426 existing human, monkey, and alpaca antibodies. The library excludes potential development liability motifs while selecting for optimal complementarity determining region (CDR) sequences and lengths that generate the diversity of this antibody set. The heavy chain library permutates CDR sequences from 100 unique CDR1s, 100 unique CDR2s, and 845 unique CDR3s within the human IGHV3-23 framework. The light chain library assembles diverse combinations of CDRs from 80 unique CDR1s, 80 unique CDR2s, and 400 unique CDR3s within the human IGKVK1-39 framework. When combined, the assembled heavy and light chain libraries yield a fully human scFv library with a diversity of 1 x 109.

heavy chain & light chain image
The Process
Library Panning & Screening Process

Go from panning to functional assays in 10-12 weeks. The process starts with phage screening the diverse Twist Ancestral scFv Library against target antigens and ends with reformatting candidate antibody fragments to full-length IgG.

You can also license the Ancestral scFv library to initiate your own in-house discovery projects. To learn more, get in touch at [email protected]

Library Planning and Screening
Library Panning & Screening Process

Go from panning to functional assays in 10-12 weeks. The process starts with phage screening the diverse Twist Ancestral scFv Library against target antigens and ends with reformatting candidate antibody fragments to full-length IgG.

You can also license the Ancestral scFv library to initiate your own in-house discovery projects. To learn more, get in touch at [email protected]

Library Planning and Screening
Proof of Concept

Proof of Concept Data

The Twist Ancestral scFv Library was successfully panned against SARS-CoV-2 Spike Protein S1. A large number of unique clones with diverse binding affinities were identified.

Uncover Anti-S1 Antibodies with High Binding Affinity

Kinetics with directly coupled anti-S1 antibodies via surface plasmon resonance identifies antibodies like TB212-12 and TB212-56 with high binding affinity for S1 and S trimer.

Uncover Anti-S1 Antibodies with High Binding Affinity
Potent Inhibition of VERO E6 Cells by FACS

Flow titration demonstrates that TB212-12 and TB212-56 show inhibition of S1 binding to ACE2-expressing VERO E6 cell

Potent Inhibition of VERO E6 Cells by FACS

Proof of Concept Data

The Twist Ancestral scFv Library was successfully panned against SARS-CoV-2 Spike Protein S1. A large number of unique clones with diverse binding affinities were identified.

Uncover Anti-S1 Antibodies with High Binding Affinity

Kinetics with directly coupled anti-S1 antibodies via surface plasmon resonance identifies antibodies like TB212-12 and TB212-56 with high binding affinity for S1 and S trimer.

Uncover Anti-S1 Antibodies with High Binding Affinity
Potent Inhibition of VERO E6 Cells by FACS

Flow titration demonstrates that TB212-12 and TB212-56 show inhibition of S1 binding to ACE2-expressing VERO E6 cell

Potent Inhibition of VERO E6 Cells by FACS
Resources